• health

• news

The Astraznica vaccine does not protect against the South African variant

In South Africa, the use of the vaccine developed by Astrazenica is stopped after a study found that it does not prevent mild-to-moderate illness in people infected with the South African strain of the corona

Tags

• Corona

• Corona virus

• Astraznica

• South Africa

• The South African mutation

Walla!

health

Monday, 08 February 2021, 10:50

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments

• Netanyahu: "I would like to add at least two weeks to the closure of the borders" ...

• Netanyahu: I will enter the government to extend the closure and ...

• Netanyahu at the beginning of the cabinet meeting discussing the extension of the closure: ...

• Experts recommend vaccinating women who are planning a pregnancy or ...

• China after inspectors banned entry into Wuhan: Saddles ...

• Netanyahu: 90% of people aged 50 and over must be vaccinated within ...

• The husband of the midwife who fell ill in Corona and is hospitalized in critical condition ...

• The world's largest vaccination campaign: India has started vaccinating ...

• Israel is a world leader in the vaccination campaign against ...

• Biden has signed war orders in Corona: we will reach 500,000 ...

• Surviving Death

In video: UK launches AstraZenica and Oxford vaccination campaign (Photo: Reuters)

In recent weeks the question that has bothered us all has been whether corona vaccines will protect against the mutations of the virus.

Now, a new study finds that in some cases - the answer is no.

According to data released yesterday (Sunday), the Astraznica vaccine does not protect against the South African variant, for mild to moderate cases.

Following the initial results of the study, South Africa has announced that it will temporarily stop using the Astrazenica vaccine.

The World Health Organization has announced it will investigate the matter.

More on Walla!

NEWS

The mysterious mystery that caused the corona numbers in India to plummet

To the full article

The University of Vittersrand in Johannesburg, which conducted the study, said in a statement that the vaccine provided only "minimal protection against mild to moderate Covid-19 infection" of the South African version.

According to the researchers, their findings "confirm the theoretical observation that the mutations seen in South Africa will allow a continuous transmission of the virus in vaccinated populations".

More on Walla!

NEWS

• In the UK they are testing whether a vaccine cocktail will be more effective

• A study found that 8% of women undergoing fertility treatment became pregnant with quarantine.

  this is the reason

• The system that helps teachers help students

The study involved 2,000 volunteers, with an average age of 31, half of whom received the Asterzanica vaccine, and the rest a placebo.

The researchers said that "protection against moderate-to-severe illness, hospitalization or death could not be assessed in this study because the target population was at low risk."

However, Astraznica emphasizes that none of the participants developed severe symptoms.

"We may not reduce the total number of cases, but there is still protection against deaths, hospitalizations and serious illnesses," Sarah Gilbert, who led the vaccine development at the Oxford Vaccine Group, told the BBC.

Astraznica later told AFP that "we believe our vaccine will still protect against a serious illness."

"The vaccine still protects against a serious illness."

Astraznica vaccine bottle (Photo: Reuters)

Apparently, the data show that the vaccine will not prevent people from contracting the South African strain, and become mild to moderate, but will protect against severe cases and reduce mortality.

However it is important to clarify that there is not yet enough data to say this with certainty.

It should also be noted that the findings have not yet been peer-reviewed.

As mentioned, in light of the alarming findings, South Africa decided to suspend the use of the British vaccine.

South Africa's health minister, Dr. Tsully McKays, said the vaccine would be suspended until scientists understood how to most effectively deploy the Astraznica vaccine. McKayes said South Africa was currently making progress with the Pfizer and Johnson & C. vaccines. Vanson.

"The vaccine leads to a decrease in the spread of the virus"

On the other hand, another study on the same vaccine published this week in the UK found that it may lead to a significant decrease in the spread of the virus.

The study, which was also not officially published and did not pass peer review, also showed that the vaccine remained effective while people waited for a second dose.

The study, conducted on 17,000 people in the UK, South Africa and Brazil, showed that protection remained at 76 per cent in the three months following the first dose.

Protection rose to 82 percent after people received the second dose.

According to the researchers, from the University of Oxford, which developed the vaccine together with Astraznica, the effect of the vaccine on the transmission of the virus is critical.

If a vaccine only prevents a person from getting seriously ill, but he can still be infected with the virus and transmit it, then everyone will have to get vaccinated to be protected.

But if the vaccine also stops the spread of the virus, it will have a greater effect on the epidemic, since any person who is vaccinated indirectly protects other people as well.

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments